Supernus Pharmaceuticals, Inc. (SUPN) News
Filter SUPN News Items
SUPN News Results
|Loading, please wait...|
SUPN News Highlights
- SUPN's 30 day story count now stands at 12.
- Over the past 20 days, the trend for SUPN's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- AVEO, AGE and ACAD are the most mentioned tickers in articles about SUPN.
Latest SUPN News From Around the Web
Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.
After a ~1.2% loss yesterday despite the FDA approval for Qelbree in attention-deficit hyperactivity disorder (“ADHD”) in those aged 6 – 17 years, Supernus Pharmaceuticals ([[SUPN]] +9.0%) is trading sharply higher today.Based on two surveys conducted by the firm, Jefferies has upgraded the stock to buy from hold expecting a larger-than-expected...
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
The FDA has approved Supernus Pharmaceuticals' (SUPN) Qelbree (SPN-812) (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder ((ADHD)) in pediatric patients 6 to 17 years of age. The approval of Qelbree is supported by data from a development program consisting of four Phase III clinical trials that studied...
Supernus Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Qelbree, its treatment for attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 17. Shares are up about 10% in Monday’s pre-market session. Supernus Pharmaceuticals (SUPN) President and Chief Executive Officer, Jack A. Khattar, said, “Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD. Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.” Andrew J. Cutler, M.D.
On Friday afternoon, Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients between the ages of 6 to 17. As a result of this regulatory update, shares of the biopharmaceutical company are rising sharply on Monday and were up by 10.2% as of 1:49 p.m. EDT after jumping by as much as 11.4% earlier in the day. It hasn't been an easy road for Supernus Pharmaceuticals' attempt to earn approval for Qelbree: The company conducted four phase 3 clinical trials with over 1,000 ADHD patients to demonstrate the safety and efficacy of this medicine.
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
Supernus shares are higher after the Food and Drug Administration cleared the company to market a new ADHD drug for children.
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug research. Among the notable approvals that came through in the month were Abecma, the first-ever cell therapy for a type of blood cancer; Fotivda, AVEO Pharmaceuticals, Inc.'s (NASDAQ: AVEO ) oral, next-generation therapy for treating advanced renal cell carcinoma; and KemPharm, Inc.'s (NASDAQ: KMPH ) Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are de...
With solid revenue growth, these stocks have the potential to more than triple over the next few years.
If you're like me, your investment watch list is overflowing with dozens of stocks and price alerts. Let's examine three biotechs trading at lower than average valuations and consider whether they might be worth putting on your watch list. Supernus Pharmaceuticals (NASDAQ: SUPN) makes drugs that treat disorders of the central nervous system, including epilepsy and Parkinson's disease.